Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy als...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Oncol
Egile Nagusiak: Gozzetti, Alessandro, Bacchiarri, Francesca, Sammartano, Vincenzo, Defina, Marzia, Sicuranza, Anna, Mecacci, Bianca, Zappone, Elisabetta, Cencini, Emanuele, Fabbri, Alberto, Raspadori, Donatella, Bocchia, Monica
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783633/
https://ncbi.nlm.nih.gov/pubmed/33415072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.570187
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak